AVRO Stock Overview
About the company
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company’s product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
AVROBIO, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.89 |
| 52 Week High | US$1.93 |
| 52 Week Low | US$0.56 |
| Beta | 1.63 |
| 1 Month Change | -44.38% |
| 3 Month Change | 17.32% |
| 1 Year Change | -43.67% |
| 3 Year Change | -93.92% |
| 5 Year Change | n/a |
| Change since IPO | -97.15% |
Recent News & Updates
Recent updates
Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK
Oct 18Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status
Sep 20AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy
Jul 13Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Nov 13
We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
Aug 10AVROBIO: Fabrazyme's Full Approval Changes Things
May 05Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Mar 08AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise
Dec 25We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth
Nov 23
AVROBIO readies $75M equity offering
Nov 19AVROBIO EPS misses by $0.19
Nov 05Shareholder Returns
| AVRO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -28.2% | -1.5% | -0.3% |
| 1Y | -43.7% | -3.4% | -14.8% |
Return vs Industry: AVRO underperformed the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: AVRO underperformed the US Market which returned -14.2% over the past year.
Price Volatility
| AVRO volatility | |
|---|---|
| AVRO Average Weekly Movement | 30.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AVRO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 30% a week.
Volatility Over Time: AVRO's weekly volatility has increased from 17% to 30% over the past year.
AVROBIO, Inc. Fundamentals Summary
| AVRO fundamental statistics | |
|---|---|
| Market Cap | US$38.96m |
| Earnings (TTM) | -US$109.08m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs AVRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVRO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 15.5% |
How did AVRO perform over the long term?
See historical performance and comparison